ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,851.70
-0.15%
S&P ASX All Technology
3,077.90
0.70%
Brent Oil
82.975
-0.66%
US Dollar vs AUD
1.49784
-0.07%
Bitcoin
70,577.83
-1.22%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Fate Therapeutics Inc (FATE)

  7. Fate Therapeutics Inc (FATE) News

FATE

Fate Therapeutics (FATE)

Fate Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:FATE
DateTimeSourceHeadlineSymbolCompany
10/05/202406:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:FATEFate Therapeutics Inc
10/05/202406:01GlobeNewswire Inc.Fate Therapeutics Reports First Quarter 2024 Financial Results and Business UpdatesNASDAQ:FATEFate Therapeutics Inc
09/05/202423:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:FATEFate Therapeutics Inc
09/05/202422:30GlobeNewswire Inc.Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell ProgramNASDAQ:FATEFate Therapeutics Inc
06/05/202422:00GlobeNewswire Inc.Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2024 Financial Results and Operational UpdatesNASDAQ:FATEFate Therapeutics Inc
04/05/202406:30GlobeNewswire Inc.Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual MeetingNASDAQ:FATEFate Therapeutics Inc
23/04/202406:30GlobeNewswire Inc.Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual MeetingNASDAQ:FATEFate Therapeutics Inc
03/04/202423:00GlobeNewswire Inc.Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:FATEFate Therapeutics Inc
03/04/202407:01GlobeNewswire Inc.Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:FATEFate Therapeutics Inc
19/03/202423:44GlobeNewswire Inc.Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private PlacementNASDAQ:FATEFate Therapeutics Inc
06/03/202408:24Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FATEFate Therapeutics Inc
06/03/202408:01GlobeNewswire Inc.Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:FATEFate Therapeutics Inc
05/03/202405:29Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:FATEFate Therapeutics Inc
02/03/202400:00GlobeNewswire Inc.Fate Therapeutics to Present at Upcoming March Investor ConferencesNASDAQ:FATEFate Therapeutics Inc
27/02/202408:10Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:FATEFate Therapeutics Inc
27/02/202408:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:FATEFate Therapeutics Inc
27/02/202408:01GlobeNewswire Inc.Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business UpdatesNASDAQ:FATEFate Therapeutics Inc
16/02/202400:00GlobeNewswire Inc.Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:FATEFate Therapeutics Inc
13/02/202410:06Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:FATEFate Therapeutics Inc
03/02/202408:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FATEFate Therapeutics Inc
03/02/202408:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FATEFate Therapeutics Inc
03/02/202408:09Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FATEFate Therapeutics Inc
03/02/202408:09Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FATEFate Therapeutics Inc
03/02/202408:01GlobeNewswire Inc.Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:FATEFate Therapeutics Inc
31/01/202408:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FATEFate Therapeutics Inc
30/01/202405:44Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:FATEFate Therapeutics Inc
26/01/202408:19Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:FATEFate Therapeutics Inc
11/01/202408:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FATEFate Therapeutics Inc
11/01/202408:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FATEFate Therapeutics Inc
11/01/202408:29Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FATEFate Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:FATE

Your Recent History

ASX
WES
Wesfarmers
ASX
ANZ
Australia And New Zealan...
ASX
XTO
S&P ASX 100
ASX
RIO
Rio Tinto
NASDAQ
GOOGL
Alphabet
ASX
WBC
Westpac Banking
NYSE
VZ
Verizon Communications
NASDAQ
NVDA
NVIDIA
NYSE
NKE
Nike
NYSE
DIS
Walt Disney
ASX
SUN
Suncorp
NYSE
XOM
Exxon Mobil
CCOM
SILVER
SILVER
ASX
BHP
BHP
NASDAQ
AAPL
Apple
FX
AUDJPY
AUD vs Yen
Delayed Upgrade Clock
ADVFN Logo

Australia
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved